This article is more than 5 years old. Information may no longer be current.
VIDEO: Develop, discuss therapeutic goals with patients to improve UC healing
ORLANDO — In this exclusive video perspective from Advances in IBD 2018, Adam Cheifetz, MD, from Beth Israel Deaconess Medical Center, discusses several of the topics he presented during the meeting, including therapeutic drug monitoring and mucosal healing.
“In patients with more aggressive disease phenotypes, more severe disease, with infliximab [Remicade, Janssen] and your other anti-TNF therapies, your best off with either combination therapy or optimizing drug concentrations based on trough windows,” he told Healio Gastroenterology and Liver Disease. “It’s most important to get these drug concentrations after induction.”
Cheifetz said the most important takeaway from the mucosal healing discussion was choosing your therapeutic goal.
“Have a discussion with your patient about what that goal is,” he said. “You want to optimize whatever therapy that patient is already on.”
Disclosure: Cheifetz reports financial ties to Miraca.